{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:34:26Z","timestamp":1790282066955,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2022JJ70110"],"award-info":[{"award-number":["2022JJ70110"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10637-024-01452-0","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T13:03:18Z","timestamp":1717419798000},"page":"369-375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis"],"prefix":"10.1007","volume":"42","author":[{"given":"Panpan","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuge","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"issue":"6411","key":"1452_CR1","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J et al (2018) Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362(6411):eaar3593. https:\/\/doi.org\/10.1126\/science.aar3593","journal-title":"Science"},{"issue":"9","key":"1452_CR2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.5732\/cjc.014.10122","volume":"33","author":"E Sharon","year":"2014","unstructured":"Sharon E, Streicher H, Goncalves P, Chen HX (2014) Immune checkpoint inhibitors in clinical trials. Chin J Cancer 33(9):434\u2013444. https:\/\/doi.org\/10.5732\/cjc.014.10122","journal-title":"Chin J Cancer"},{"issue":"10","key":"1452_CR3","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the Immune-related adverse effects of Immune Checkpoint inhibitors: a review. JAMA Oncol 2(10):1346\u20131353. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1051","journal-title":"JAMA Oncol"},{"issue":"2","key":"1452_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1634\/theoncologist.2018-0162","volume":"25","author":"C Hsu","year":"2020","unstructured":"Hsu C, Marshall JL, He AR (2020) Workup and management of Immune-mediated hepatobiliary pancreatic toxicities that develop during Immune checkpoint inhibitor treatment. Oncologist 25(2):105\u2013111. https:\/\/doi.org\/10.1634\/theoncologist.2018-0162","journal-title":"Oncologist"},{"issue":"2","key":"1452_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/CJI.0000000000000202","volume":"41","author":"JM Michot","year":"2018","unstructured":"Michot JM, Ragou P, Carbonnel F, Champiat S, Voisin AL, Mateus C et al (2018) Significance of Immune-related lipase increase Induced by Antiprogrammed Death-1 or death Ligand-1 antibodies: a brief communication. J Immunother 41(2):84\u201385. https:\/\/doi.org\/10.1097\/CJI.0000000000000202","journal-title":"J Immunother"},{"issue":"2","key":"1452_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/1742-6723.12718","volume":"29","author":"AJ Lomax","year":"2017","unstructured":"Lomax AJ, McNeil C (2017) Acute management of autoimmune toxicity in cancer patients on immunotherapy: common toxicities and the approach for the emergency physician. Emerg Med Australas 29(2):245\u2013251. https:\/\/doi.org\/10.1111\/1742-6723.12718","journal-title":"Emerg Med Australas"},{"key":"1452_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","volume":"8","author":"V Kumar","year":"2017","unstructured":"Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017) Current diagnosis and management of Immune related adverse events (irAEs) Induced by Immune checkpoint inhibitor therapy. Front Pharmacol 8:49. https:\/\/doi.org\/10.3389\/fphar.2017.00049","journal-title":"Front Pharmacol"},{"key":"1452_CR8","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2017.00730","volume":"8","author":"PF Wang","year":"2017","unstructured":"Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW et al (2017) Immune-related adverse events Associated with Anti-PD-1\/PD-L1 treatment for malignancies: a Meta-analysis. Front Pharmacol 8:730. https:\/\/doi.org\/10.3389\/fphar.2017.00730","journal-title":"Front Pharmacol"},{"issue":"4","key":"1452_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","volume":"19","author":"J George","year":"2019","unstructured":"George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S et al (2019) Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis. Pancreatology 19(4):587\u2013594. https:\/\/doi.org\/10.1016\/j.pan.2019.04.015","journal-title":"Pancreatology"},{"issue":"24","key":"1452_CR10","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.2169\/internalmedicine.7366-21","volume":"60","author":"M Ueno","year":"2021","unstructured":"Ueno M, Tsuji Y, Yokoyama T, Koyama T, Uenishi Y, Ishida E, Mizuno M (2021) Fatal Immune checkpoint inhibitor-related pancreatitis. Intern Med 60(24):3905\u20133911. https:\/\/doi.org\/10.2169\/internalmedicine.7366-21","journal-title":"Intern Med"},{"issue":"8","key":"1452_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/01.mcg.0000173929.60115.b4","volume":"39","author":"CD Trivedi","year":"2005","unstructured":"Trivedi CD, Pitchumoni CS (2005) Drug-induced pancreatitis: an update. J Clin Gastroenterol 39(8):709\u2013716. https:\/\/doi.org\/10.1097\/01.mcg.0000173929.60115.b4","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"1452_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/MPA.0b013e3182588c91","volume":"42","author":"DM Almeida","year":"2013","unstructured":"Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM (2013) Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report. Pancreas 42(1):177\u2013178. https:\/\/doi.org\/10.1097\/MPA.0b013e3182588c91","journal-title":"Pancreas"},{"issue":"5","key":"1452_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1046\/j.1365-2125.2000.00196.x","volume":"49","author":"IA Eland","year":"2000","unstructured":"Eland IA, Alvarez CH, Stricker BH, Rodr\u00edguez LA (2000) The risk of acute pancreatitis associated with acid-suppressing drugs. Br J Clin Pharmacol 49(5):473\u2013478. https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00196.x","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1452_CR14","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1097\/MJT.0000000000001199","volume":"29","author":"S Paulraj","year":"2020","unstructured":"Paulraj S, Ashok Kumar P, Habib G, Shah A, Amzuta I (2020) Bevacizumab and Pancreatitis; an Uncommon Association. Am J Ther 29(2):e261\u2013e263. https:\/\/doi.org\/10.1097\/MJT.0000000000001199","journal-title":"Am J Ther"},{"issue":"2","key":"1452_CR15","first-page":"286","volume":"37","author":"D Shintani","year":"2016","unstructured":"Shintani D, Yoshida H, Imai Y, Fujiwara K (2016) Acute pancreatitis induced by paclitaxel and carboplatin therapy in an ovarian cancer patient. Eur J Gynaecol Oncol 37(2):286\u2013287","journal-title":"Eur J Gynaecol Oncol"},{"issue":"17","key":"1452_CR16","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of Immune-related adverse events in patients treated with Immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"issue":"18","key":"1452_CR17","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.clinbiochem.2017.07.003","volume":"50","author":"OZ Ismail","year":"2017","unstructured":"Ismail OZ, Bhayana V (2017) Lipase or amylase for the diagnosis of acute pancreatitis? Clin Biochem 50(18):1275\u20131280. https:\/\/doi.org\/10.1016\/j.clinbiochem.2017.07.003","journal-title":"Clin Biochem"},{"issue":"1","key":"1452_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.6004\/jadpro.2020.11.1.3","volume":"11","author":"BB Rogers","year":"2020","unstructured":"Rogers BB, Cuddahy T, Zawislak C (2020) Management of Acute Pancreatitis Associated with checkpoint inhibitors. J Adv Pract Oncol 11(1):49\u201362. https:\/\/doi.org\/10.6004\/jadpro.2020.11.1.3","journal-title":"J Adv Pract Oncol"},{"issue":"6","key":"1452_CR19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1159\/000318809","volume":"10","author":"ST Chari","year":"2010","unstructured":"Chari ST, Kloeppel G, Zhang L, Notohara K, Lerch MM, Shimosegawa T (2010) Histopathologic and clinical subtypes of autoimmune pancreatitis: the honolulu consensus document. Pancreatology 10(6):664\u2013672. https:\/\/doi.org\/10.1159\/000318809","journal-title":"Pancreatology"},{"issue":"3","key":"1452_CR20","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/MPA.0b013e3182142fd2","volume":"40","author":"T Shimosegawa","year":"2011","unstructured":"Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M et al (2011) International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 40(3):352\u2013358. https:\/\/doi.org\/10.1097\/MPA.0b013e3182142fd2","journal-title":"Pancreas"},{"issue":"4","key":"1452_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00535-018-1440-8","volume":"53","author":"K Uchida","year":"2018","unstructured":"Uchida K, Okazaki K (2018) Clinical and pathophysiological aspects of type 1 autoimmune pancreatitis. J Gastroenterol 53(4):475\u2013483. https:\/\/doi.org\/10.1007\/s00535-018-1440-8","journal-title":"J Gastroenterol"},{"issue":"9","key":"1452_CR22","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/s41395-018-0146-0","volume":"113","author":"SJS Nagpal","year":"2018","unstructured":"Nagpal SJS, Sharma A, Chari ST (2018) Autoimmune pancreatitis. Am J Gastroenterol 113(9):1301. https:\/\/doi.org\/10.1038\/s41395-018-0146-0","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1452_CR23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s42003-020-01308-2","volume":"3","author":"R Tanaka","year":"2020","unstructured":"Tanaka R, Ichimura Y, Kubota N, Saito A, Nakamura Y, Ishitsuka Y et al (2020) Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6. Commun Biol 3(1):571. https:\/\/doi.org\/10.1038\/s42003-020-01308-2","journal-title":"Commun Biol"},{"issue":"8","key":"1452_CR24","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","volume":"57","author":"DE Kleiner","year":"2012","unstructured":"Kleiner DE, Berman D (2012) Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 57(8):2233\u20132240. https:\/\/doi.org\/10.1007\/s10620-012-2140-5","journal-title":"Dig Dis Sci"},{"issue":"24","key":"1452_CR25","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.2169\/internalmedicine.9565-22","volume":"61","author":"M Hirota","year":"2022","unstructured":"Hirota M, Murakami K, Koiwai A, Kawamura K, Yoshino Y, Takasu A et al (2022) Neutrophil infiltration and acinar-ductal Metaplasia are the Main pathological findings in Pembrolizumab-induced pancreatitis. Intern Med 61(24):3675\u20133682. https:\/\/doi.org\/10.2169\/internalmedicine.9565-22","journal-title":"Intern Med"},{"issue":"6","key":"1452_CR26","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/s12328-021-01499-z","volume":"14","author":"K Ofuji","year":"2021","unstructured":"Ofuji K, Hiramatsu K, Nosaka T, Naito T, Takahashi K, Matsuda H et al (2021) Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer. Clin J Gastroenterol 14(6):1692\u20131699. https:\/\/doi.org\/10.1007\/s12328-021-01499-z","journal-title":"Clin J Gastroenterol"},{"key":"1452_CR27","doi-asserted-by":"publisher","first-page":"627612","DOI":"10.3389\/fonc.2021.627612","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, Zhang H, Zhou L, Li W, Yang L, Li W et al (2021) Immunotherapy-Associated pancreatic adverse events: current understanding of their mechanism, diagnosis, and management. Front Oncol 11:627612. https:\/\/doi.org\/10.3389\/fonc.2021.627612","journal-title":"Front Oncol"},{"issue":"4","key":"1452_CR28","doi-asserted-by":"publisher","first-page":"e38315","DOI":"10.7759\/cureus.38315","volume":"15","author":"A Ashfaq","year":"2023","unstructured":"Ashfaq A, Thalambedu N, Atiq MU (2023) Acute Pancreatitis secondary to Pembrolizumab-Induced Hypertriglyceridemia. Cureus 15(4):e38315. https:\/\/doi.org\/10.7759\/cureus.38315","journal-title":"Cureus"},{"issue":"4","key":"1452_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK et al (2022) Management of immunotherapy-related toxicities, Version 1.2022, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw 20(4):387\u2013405. https:\/\/doi.org\/10.6004\/jnccn.2022.0020","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1452_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA et al (2019) Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer 7(1):31. https:\/\/doi.org\/10.1186\/s40425-019-0502-7","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1452_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/jgh3.12875","volume":"7","author":"C Hana","year":"2023","unstructured":"Hana C, Rehman T, Park K, Carracedo Uribe C, Aung PP, Hunis B et al (2023) Pancreatic adverse events in patients treated with immune checkpoint inhibitors. JGH Open 7(3):204\u2013207. https:\/\/doi.org\/10.1002\/jgh3.12875","journal-title":"JGH Open"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01452-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01452-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01452-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T10:05:37Z","timestamp":1723716337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01452-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1452"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01452-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"8 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require an ethical board approval because the study was a retrospective study and did not involve sensitive personal information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}